Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Santen Bags Rights to Osmotica’s Droopy Eyelid Drug
July 29, 2020
- Eisai, DeNA Launch Smartphone App for Dementia Prevention
July 29, 2020
- Ibrance Now Available in Tablet Forms: Pfizer Japan
July 29, 2020
- Pfizer Japan Has Different Interpretation on Lyrica Patent Ruling
July 29, 2020
- Novartis Links Up with Ehime Pref., Ehime Univ. to Fuel Cardiovascular Disease Prevention
July 29, 2020
- Chugai’s Half-Year Earnings Surge on Actemra/Hemlibra Exports
July 28, 2020
- EU Panel Gives Thumbs-Up to Avastin Biosimilar
July 28, 2020
- Daiichi Sankyo, AstraZeneca to Collaborate for Another ADC
July 28, 2020
- Lyrica Expected to Face Generic Onslaught by Year’s End as Patent Ruled Invalid
July 28, 2020
- EU Panel Backs Kyowa Kirin’s Crysvita for Adult XLH
July 28, 2020
- StemRIM Bags 1.7 Billion Yen from Shionogi for Expanded Deal on Regeneration-Inducing Medicine
July 28, 2020
- Chugai, Biofourmis to Develop Digital Solution to Objectively Assess Endometriosis Pain
July 27, 2020
- Astellas Earns NIH Grant for Potential Opioid Use Disorder Med
July 27, 2020
- Dosing of Low-Dose COVID-19 Vaccine Completed: AnGes PI/II Study
July 27, 2020
- Daiichi Sankyo Inks ADC Pact with Gustave Roussy
July 27, 2020
- Nihon Chouzai Launches Drug Information Service with Standard Formulary Including Few New Meds
July 27, 2020
- Chiome to Launch First-in-Human Trial for Anti-DLK-1 Antibody
July 22, 2020
- Shonan iPark’s VC Consortium Now Up and Running
July 22, 2020
- 9-Valent HPV Vaccine Hits Finish Line, but Japan Launch Schedule Uncertain with High Global Demand
July 22, 2020
- Mochida, Shimane Univ. Start Collaborative Research on New Treatment for Joint Disease
July 22, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…